Global Markets Direct’s, ‘Birch Pollen Allergy - Pipeline Review, H1 2016’, provides an overview of the Birch Pollen Allergy pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Birch Pollen Allergy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Birch Pollen Allergy and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
- The report provides a snapshot of the global therapeutic landscape of Birch Pollen Allergy - The report reviews pipeline therapeutics for Birch Pollen Allergy by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Birch Pollen Allergy therapeutics and enlists all their major and minor projects - The report assesses Birch Pollen Allergy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Birch Pollen Allergy
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Birch Pollen Allergy - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Birch Pollen Allergy pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table Of Contents
Birch Pollen Allergy - Pipeline Review, H1 2016 Table of Contents Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Birch Pollen Allergy Overview 7 Therapeutics Development 8 Pipeline Products for Birch Pollen Allergy - Overview 8 Birch Pollen Allergy - Therapeutics under Development by Companies 9 Birch Pollen Allergy - Pipeline Products Glance 10 Late Stage Products 10 Clinical Stage Products 11 Early Stage Products 12 Birch Pollen Allergy - Products under Development by Companies 13 Birch Pollen Allergy - Companies Involved in Therapeutics Development 14 ALK-Abello A/S 14 Allergopharma GmbH and Co. KG 15 Allergy Therapeutics Plc 16 Anergis SA 17 Biomay AG 18 Circassia Pharmaceuticals Plc 19 HAL Allergy BV 20 Stallergenes S.A. 21 Birch Pollen Allergy - Therapeutics Assessment 22 Assessment by Monotherapy Products 22 Assessment by Target 23 Assessment by Route of Administration 24 Assessment by Molecule Type 26 Drug Profiles 28 Allergen for Birch Allergy - Drug Profile 28 Product Description 28 Mechanism of Action 28 RandD Progress 28 Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 29 Product Description 29 Mechanism of Action 29 RandD Progress 29 Allergen for Birch Pollen Induced Allergic Rhinoconjunctivitis - Drug Profile 31 Product Description 31 Mechanism of Action 31 RandD Progress 31 AllerT - Drug Profile 32 Product Description 32 Mechanism of Action 32 RandD Progress 32 BM-31 - Drug Profile 35 Product Description 35 Mechanism of Action 35 RandD Progress 35 PL-102 - Drug Profile 36 Product Description 36 Mechanism of Action 36 RandD Progress 36 Pollinex Quattro Tree - Drug Profile 37 Product Description 37 Mechanism of Action 37 RandD Progress 37 rBet v1-FV - Drug Profile 39 Product Description 39 Mechanism of Action 39 RandD Progress 39 STG-210 - Drug Profile 40 Product Description 40 Mechanism of Action 40 RandD Progress 40 Vaccine for Birch Pollen Allergy - Drug Profile 41 Product Description 41 Mechanism of Action 41 RandD Progress 41 Birch Pollen Allergy - Recent Pipeline Updates 42 Birch Pollen Allergy - Dormant Projects 44 Birch Pollen Allergy - Discontinued Products 45 Birch Pollen Allergy - Product Development Milestones 46 Featured News and Press Releases 46 Sep 01, 2015: First patient recruited in Pollinex Quattro Birch dose ranging study in Germany and Austria 46 Apr 01, 2015: Anergis Announces Completion of Treatment in AllerT Phase II Dose-Ranging Trial 46 Mar 10, 2015: Positive Outcome of the PURETHAL Birch RUSH Study Results in an Approved, Accelerated up-dosing Regimen 47 Feb 23, 2015: Anergis Presents Sustained Efficacy Data from its AllerT Phase IIb Trial at the AAAAI Annual Meeting 47 Dec 11, 2014: Anergis Starts Phase II Dose Ranging Trial with Birch Pollen Allergy Vaccine AllerT 48 Sep 16, 2014: Anergis Reports Positive Long-Term Clinical Efficacy of Lead Compound AllerT 48 May 27, 2014: Anergis to Present New COP Allergy Vaccine Data at EAACI Conference 2014 in Copenhagen 49 Apr 23, 2014: Anergis Completes Enrolment in the Long-Term Efficacy Trial of Lead Compound AllerT 49 Feb 27, 2014: Phase IIb Results of AnergisÂ´ Lead Compound AllerT to be Presented at 2014 AAAAI Annual Meeting in San Diego 50 Oct 21, 2013: Immunology Data Further Underline the Positive Outcome of a Phase IIb Trial of Anergis's Birch Pollen Allergy Vaccine AllerT 50 Appendix 51 Methodology 51 Coverage 51 Secondary Research 51 Primary Research 51 Expert Panel Validation 51 Contact Us 51 Disclaimer 52
List of Tables Number of Products under Development for Birch Pollen Allergy, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Comparative Analysis by Late Stage Development, H1 2016 10 Comparative Analysis by Clinical Stage Development, H1 2016 11 Comparative Analysis by Early Stage Development, H1 2016 12 Products under Development by Companies, H1 2016 13 Birch Pollen Allergy - Pipeline by ALK-Abello A/S, H1 2016 14 Birch Pollen Allergy - Pipeline by Allergopharma GmbH and Co. KG, H1 2016 15 Birch Pollen Allergy - Pipeline by Allergy Therapeutics Plc, H1 2016 16 Birch Pollen Allergy - Pipeline by Anergis SA, H1 2016 17 Birch Pollen Allergy - Pipeline by Biomay AG, H1 2016 18 Birch Pollen Allergy - Pipeline by Circassia Pharmaceuticals Plc, H1 2016 19 Birch Pollen Allergy - Pipeline by HAL Allergy BV, H1 2016 20 Birch Pollen Allergy - Pipeline by Stallergenes S.A., H1 2016 21 Assessment by Monotherapy Products, H1 2016 22 Number of Products by Stage and Target, H1 2016 23 Number of Products by Stage and Route of Administration, H1 2016 25 Number of Products by Stage and Molecule Type, H1 2016 27 Birch Pollen Allergy Therapeutics - Recent Pipeline Updates, H1 2016 42 Birch Pollen Allergy - Dormant Projects, H1 2016 44 Birch Pollen Allergy - Discontinued Products, H1 2016 45
List of Figures Number of Products under Development for Birch Pollen Allergy, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Comparative Analysis by Clinical Stage Development, H1 2016 11 Comparative Analysis by Early Stage Products, H1 2016 12 Assessment by Monotherapy Products, H1 2016 22 Number of Products by Routes of Administration, H1 2016 24 Number of Products by Stage and Routes of Administration, H1 2016 24 Number of Products by Molecule Types, H1 2016 26 Number of Products by Stage and Molecule Types, H1 2016 26